| 10/14/2011 | CV | Cephalon's 2.5%, 2% notes convertible into cash following Teva merger
|
| 8/22/2011 | CV | Cephalon announces expected make-whole conversion amounts for notes
|
| 5/2/2011 | CVEMIG | Teva plans to use cash, bonds to acquire Cephalon for $6.8 billion
|
| 5/2/2011 | CV | Market Commentary: Cephalon adds outright, flat on hedge after Teva bid; Teva adds too; International Coal up
|
| 4/4/2011 | CV | Market Commentary: Horizon Lines takes another leg down; Life Technologies slips; Dendreon up; Meritor steady
|
| 4/1/2011 | CV | Market Commentary: New A123 slightly higher outright; Ramco slips below par; Meritor lower after cutting outlook
|
| 3/31/2011 | CV | Market Commentary: Greenbrier expands on debut; Ramco-Gershenson to price; Dendreon in line on drug news
|
| 3/30/2011 | CV | Market Commentary: Cephalon comes in on hedge after Valeant bid; new InterDigital up; Greenbrier adds in gray
|
| 3/14/2011 | CV | Market Commentary: USEC drops dollar neutral on Japan's nuclear crisis; Chesapeake up; Illumina, RAIT on tap
|
| 2/15/2011 | CV | Market Commentary: Prospect Capital trades up after pricing another $150 million convertible; Cephalon steady
|
| 8/13/2010 | CV | Market Commentary: PDL BioPharma falls 3 points outright; Qwest active on extended tender; Cephalon improves
|
| 7/21/2010 | CV | Market Commentary: Apache up a little in the gray; Genco quiet ahead of pricing; United Rentals, Cephalon add
|
| 6/28/2010 | CV | Market Commentary: Convertibles mixed on light volume; Navistar better; ProLogis down in line; Cephalon adds
|
| 6/1/2010 | CVLM | Cephalon calls its zero-coupon putable convertibles due 2033 at 100.25
|
| 4/9/2010 | CV | Market Commentary: Convertibles action crimped by low vol., vacations; Cephalon, Human Genome gain; Ford off
|
| 3/2/2010 | CV | Market Commentary: Newmont falls; Human Genome up on earnings, health care names bid higher; Annaly sells add-on
|
| 2/12/2010 | CV | Cephalon's 2% convertible notes, 0% convertibles are now convertible
|
| 12/31/2009 | CV | Outlook 2010: U.S. convertible secondary market set for 'milder' year after stellar 2009 returns
|
| 12/3/2009 | CV | Market Commentary: Medtronic still active; CompuCredit sinks on dividend news; bank preferreds show gains
|
| 12/1/2009 | CV | Market Commentary: Convertibles action revives; gold names in focus; Energy XXI, Sino-Forest launch new deals
|
| 11/24/2009 | CV | Market Commentary: Medtronic above par after earnings beat; Jefferies sinks; Cephalon rebounds after weakness
|
| 11/23/2009 | CV | Market Commentary: Cephalon trades mixed on disappointing drug study news; Tyson slips; TRW Automotive adds
|
| 10/27/2009 | CV | Market Commentary: Convertibles mostly weaker; Gaylord drops below 90; Ferro down 2.5 points; ProLogis gains
|
| 7/8/2009 | CV | Market Commentary: Amgen trades actively on positive trial news; Equinix dips but pares losses; Vale edges up
|
| 6/3/2009 | CV | Market Commentary: Convertibles quiet as players eye JetBlue, Biovail, Steel Dynamics; Cephalon, Human Genome up
|
| 5/22/2009 | CV | Cephalon greenshoe exercised, lifts 2.5% convertibles to $500 million
|
| 5/21/2009 | CV | Market Commentary: Cephalon adds despite 'tough environment'; Hertz, Saks, Regions Financial slip on first day
|
| 5/21/2009 | CV | New Issue: Cephalon prices upsized $435 million five-year convertibles to yield 2.5%, up 15%
|
| 5/20/2009 | CV | Cephalon $350 million five-year convertibles to yield 2.5%-3%, up 10%-15%
|
| 5/20/2009 | CV | Market Commentary: FPL trades steady to slightly lower on debut; Hertz gains in gray; Cephalon launches deal
|
| 5/20/2009 | CVHY | Cephalon files automatic stock, debt, convertibles, warrants shelf
|
| 5/6/2009 | CV | Cephalon lacks cash to fund all 2%, 0% convertibles if converted
|
| 3/17/2009 | CV | Market Commentary: Alcoa up in gray, markets expects bigger, repriced deal; Citi slips, seen cheap; Johnson Controls hold firm
|
| 11/26/2008 | CV | Market Commentary: Convertibles steady to higher in line with stocks; Chesapeake Energy gains; Ford, Cephalon steady
|
| 9/13/2007 | CV | Market Commentary: Countrywide stirs drink; Prudential up on rating; Cephalon sinks on drug concerns
|
| 4/2/2007 | CV | Market Commentary: Cephalon improves on FDA letter; Amgen remains soft on safety risks; issue pipeline seen healthy
|
| 12/20/2006 | CV | Cephalon exchanges $100 million of 2% convertible notes due 2015
|
| 12/19/2006 | CV | Cephalon exchanges $337 million of zero-coupon convertible notes
|
| 9/26/2006 | CV | Market Commentary: Advanced Medical, PMC-Sierra falls on warnings; Cephalon gains on drug nod; ChipMOS prices
|
| 8/10/2006 | CV | Market Commentary: Andrew, ImClone fall on failed buyouts; BRE, Digital Realty climb on debuts; Cephalon firm as drug flops
|
| 7/31/2006 | CV | Market Commentary: Scottish Re hit by put worries; Cephalon swings; SanDisk flat, M-Systems gains on deal; Itron solid in gray
|
| 6/30/2006 | CV | Market Commentary: Cephalon climbs on drug's progress; General Motors gains with stock; Health Management gets sweeter
|
| 6/26/2006 | CV | Market Commentary: Intel, Amgen under pressure; Inco rises; Chesapeake launches mandatories offering
|
| 5/12/2006 | BTCV | New Issue: Merrill Lynch prices $15 million 3% capped appreciation notes linked to biotech stock basket
|
| 5/3/2006 | CV | Market Commentary: Cephalon falls, PDL widens on results; NPS falls, MGI climbs on FDA news; XM firm despite lawsuits
|
| 5/2/2006 | CV | Market Commentary: Apex Silver falls on Bolivia concerns; Quicksilver gains on earnings anticipation; Sirius up on guidance
|
| 4/19/2006 | CV | Market Commentary: ExpressJet stands firm on lost business; Gilead deal priced cheaper than talk; Cephalon gains on new data
|
| 3/27/2006 | CV | Market Commentary: Lucent preferreds climb on hopes of post-merger tender; Time Warner Telecom stock upgrade boost
|
| 3/24/2006 | CV | Market Commentary: Cephalon setback positive for hedged players; Lucent strengthens on merger talks; BioMarin starts strong
|
| 3/23/2006 | CV | Market Commentary: BioMarin new deal gets thumbs-up; YRC weaker on poor outlook; Cephalon fails to get FDA nod
|
| 3/22/2006 | CV | Market Commentary: General Motors rises on union deal; Cephalon see-saws on drug prospects; Interpublic cut by S&P
|
| 3/10/2006 | CV | Market Commentary: Nortel holds firm on cross-default hopes; American Axle survives downgrade but JetBlue crashes
|
| 3/3/2006 | CV | Market Commentary: Intel holds up on hedged basis despite stock slide; Citigroup says convertible arbitrage paid off in February
|
| 2/17/2006 | CV | Market Commentary: Citadel gains on rumors of put-seeking hedge funds; Amgen's new issues continue week's climb
|
| 2/16/2006 | CV | Market Commentary: Amgen convertibles active in trade; Halliburton gains; XM Satellite lower
|
| 2/15/2006 | CV | Market Commentary: New Amgen convertibles lift in active trade; Cephalon rises on guidance, Delta Air Lines weakens
|
| 2/2/2006 | CV | Market Commentary: ImClone steady despite lack of Bristol-Myers interest; Teva under pressure; Omnicare edges lower
|
| 1/18/2006 | CV | Market Commentary: Techs dominate convertibles market; Intel drops outright but expands on a hedged basis, AMD adds
|
| 1/10/2006 | CV | Market Commentary: LifePoint Hospitals, MGI Pharma convertibles weaker on lower guidance; Cephalon jumps; GM mixed
|
| 1/6/2006 | CV | Market Commentary: Convertibles market moves mostly in-line, dollar neutral; Best Buy, Cephalon gain; Affymetrix drops
|
| 1/4/2006 | CV | Market Commentary: Convertible market sees broad-based gains, GM, Ford lift; airlines better, Calpine adds points
|
| 1/3/2006 | CV | Market Commentary: Wyeth convertibles up on pact; Cephalon adds; Mercury Interactive mostly flat
|
| 12/23/2005 | CV | Market Commentary: Albertson's trades lower in active trade; Wyeth, Omnicare gain; GM sees light buying
|
| 12/22/2005 | CV | Market Commentary: Cephalon convertibles gain on patent agreement; SFBC up on possible sale; Albertson's, Placer lose
|
| 12/9/2005 | CV | Market Commentary: Cephalon, Teva gain on patent settlement; eyes turn toward Omnicare; Alltel mostly quiet
|
| 12/6/2005 | CV | Market Commentary: Kansas City Southern gains on debut; U.S. Bancorp steady after re-offer; St. Jude Medical prices
|
| 11/8/2005 | CV | Market Commentary: Medtronic, Lucent, EDS, Cephalon lower in weak market; Blockbuster, Maverick, Equinix to price
|
| 11/7/2005 | CV | Market Commentary: Northwest, AMR higher as oil declines; Genzyme eases but Cephalon edges higher
|
| 11/1/2005 | CV | Market Commentary: Qwest, Chesapeake Energy to price $2 billion-plus in convertibles; new IPC paper trades actively
|
| 10/24/2005 | CV | Market Commentary: Cephalon, Reebok, Nextel Partners lose; Albertson's, Halliburton gain; Essex Partners set to price
|
| 9/20/2005 | CV | Market Commentary: US Airways, Toreador launch new deals, bringing calendar to five; Sepracor, Cephalon up
|
| 9/15/2005 | CV | Market Commentary: Airlines under pressure; GM, Ford mostly lower; Cephalon higher, Amgen firm
|
| 9/6/2005 | CV | Market Commentary: Chiron trades mixed, but Curagen gains; Dobson Communications to price $150 million issue
|
| 8/31/2005 | CV | Market Commentary: Moderate buying lifts convertibles of Cephalon, Micron, Maxtor; Emdeon, Mercury Interactive see interest
|
| 8/18/2005 | CV | Market Commentary: Six Flags selling on upswing from Snyder's move; Northwest, Delta drift higher, Charming Shoppes up
|
| 7/12/2005 | BTCV | Cephalon to buy $511.7 million of 21/2% convertibles in tender
|
| 7/11/2005 | CV | Market Commentary: Northwest Airlines spurs airlines convertibles; Schlumberger extends gains; but biotech, technology ease
|
| 7/1/2005 | BTCV | Cephalon greenshoe exercised, pushing 2% convertibles offer to $920 million
|
| 6/30/2005 | CV | Market Commentary: Saks, Kodak and General Mills trade in a mixed convertibles market; June marks improvements
|
| 6/29/2005 | CV | Market Commentary: CV Therapeutics' new deal gains, supporting biotechs; Mirant trades in heavy volume; General Mills eases
|
| 6/24/2005 | CV | Market Commentary: Convertibles mostly extend losses a second day; biotechs waver, but some energy issues see more gains
|
| 6/14/2005 | CV | Market Commentary: Convertibles see more selling ahead of June redemptions; GM, Ford higher, but Calpine, Northwest sink
|
| 6/13/2005 | CV | Market Commentary: Invitrogen launches $300 million convertible; Connetics, Cephalon stir market; Northwest hits turbulence
|
| 6/10/2005 | CV | Cephalon announces tender offer for 21/2% convertible subordinated notes due 2006
|
| 6/9/2005 | CV | Market Commentary: Calpine convertibles mixed after news whammy; market firms on fewer redemptions
|
| 6/6/2005 | CV | Market Commentary: Providian convertibles react flatly to Washington Mutual takeover; GM off before stockholders meet
|
| 6/3/2005 | CV | Market Commentary: Symmetricom prices wide, still breaks below par; Cephalon off to 98; Impax bid up; Doral eyed
|
| 6/2/2005 | CV | Market Commentary: Cephalon suffers in aftermarket; Joy Global pulled; Symmetricom at bat; Elan retreats on drug news
|
| 6/2/2005 | CV | New Issue: Cephalon sells $800 million convertible at 2.0%, up 10%; hedges push premium to 60%
|
| 6/1/2005 | CV | Cephalon overnight $800 million convertible talked at 1.5%-2.0%, up 10%-14%
|
| 6/1/2005 | CV | Market Commentary: Cephalon in overnight market; Elan bounces; Beazer better; airline paper dips
|
| 6/1/2005 | CV | Cephalon to tender for 21/2% convertibles with some proceeds from new deal
|
| 5/18/2005 | CV | Market Commentary: Xoma, deCode, Cephalon buyers seen; XM, Sirius at odds in race; Beverly auction in second round
|
| 5/16/2005 | CV | Market Commentary: Level 3 bonds indifferent to unit IPO; Fannie Mae bounces then retreats; TOP Tankers afloat anew
|
| 4/15/2005 | CV | Market Commentary: GM, Ford selling accelerates; El Paso, Calpine, NRG plunge; Ivax, Teva lose; Lucent, Tyco unwound
|
| 12/16/2004 | CV | Cephalon exchanges 96.5%, 98.7% of 0% convertibles
|
| 11/16/2004 | CV | Cephalon starts exchange for 0% convertibles
|
| 9/7/2004 | CV | Market Commentary: Tyco lower ahead of buybacks; Cephalon 0s fall, 2.5s steady; El Paso, Calpine higher; Valero firm
|
| 11/4/2003 | CV | S&P: Cephalon ratings unaffected on merger
|
| 10/17/2003 | CV | Market Commentary: XL holds up against stock slide on warning, boost to reserves; new Getronics euro issue zooms
|
| 9/25/2003 | CV | Market Commentary: Pharma Resources gains to 104 despite complaint; Bristol-Myers jumbo seen offered at par in gray
|
| 9/11/2003 | CV | Market Commentary: Cephalon, Tekelec bid up as players position for upsurge; airlines higher in 9/11 trading
|
| 9/10/2003 | CV | Market Commentary: Energy bucks downward trend; overall sentiment positive; telecoms, tech down but Level 3 up
|
| 8/5/2003 | CV | Market Commentary: Further cheapening noted, but many buyers waiting in wings; new deal slate remains active
|
| 8/4/2003 | CV | Silicon Graphics pulls exchange offer
|
| 6/17/2003 | CV | Cephalon to redeem 51/4% convertibles
|
| 6/16/2003 | CV | Market Commentary: ICOS, Lattice at bat; buzz puts Nextel Partners eyeing another convert after new junk offering
|
| 6/12/2003 | CV | Cephalon says $150 million greenshoe exercised, raising convertibles to $750 million
|
| 6/12/2003 | CV | Market Commentary: Yield-grabbers reach for busted convertibles, distressed issues; new paper mixed in secondary
|
| 6/11/2003 | CV | Market Commentary: Xerox emerges as a mandatory; Mirant in freefall; Tyco gains on unit sale talk; airlines fly high
|
| 6/10/2003 | CV | Moody's rates new IOS notes Ba1
|
| 6/6/2003 | CV | New Issue: Cephalon $600 million convertibles yield 0%, up 23.8% and 0%, up 17.6%
|
| 6/6/2003 | CV | Market Commentary: Convertibles see record week with 16 deals totaling $4.47 billion; Cephalon, Continental climb
|
| 6/5/2003 | CV | Cephalon $600 million two-part convertibles talked to yield 0%, up 21-26% and up 15-20%
|
| 6/5/2003 | CV | Market Commentary: Continental soars past 107; five new deals totaling $1.23 billion at bat after closing bell
|
| 5/15/2003 | CV | Cephalon buys back $7 million convertibles
|
| 10/2/2002 | CV | Market Commentary: Charter, EDS, El Paso, GM, others fall on plethora of ill-boding news
|
| 7/12/2002 | CV | Market Commentary: Market holds firm against dip in stocks as more buyers emerge
|
| 7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
| 5/17/2002 | CV | Market Commentary: LifePoint gains in hungry market; El Paso drops on "bad" news
|
| 4/5/2002 | CV | Market Commentary: Adelphia gains on hiring advisors; Getty Images soars on EPS revision; Genentech falls
|
| 2/4/2002 | CV | Market Commentary: Convertibles plunge as stocks dive, Solutia nixes new deal
|
| 1/9/2002 | CV | Market Commentary: Convertibles lower on extended profit taking as new deals emerge
|
| 1/4/2002 | CV | Market Commentary: Convertibles higher as prospects of new deals spur activity
|
| 12/12/2001 | CV | Market Commentary: Convertible market broadly mixed on Enron hype, new issues,
|
| 12/11/2001 | CV | Cephalon says greenshoe exercised, raising convertibles to $600 million
|
| 12/7/2001 | CV | Market Commentary: Convertible market slides as stock enthusiasm withers, no new deals
|
| 12/6/2001 | CV | Market Commentary: Convertible market slips on thwarted rally in stocks; new issues mixed
|
| 12/6/2001 | CV | New Issue: Cephalon upsized $500 million convertibles at 2.5% yield, up 17%
|
| 12/5/2001 | CV | Cephalon $300 million convertibles price talk tightened to 2.5-2.75% yield, 17% premium
|
| 12/5/2001 | CV | Market Commentary: Convertible market roars higher as stocks rally, new deals surge
|
| 12/4/2001 | CV | Cephalon $300 million convertibles talked at 2.75-3.25% yield, 12-17% premium
|
| 12/4/2001 | CV | Market Commentary: Convertible market moves higher, gets spate of new deals lineup
|
| 12/3/2001 | CV | Convertible market pulls back modestly as stocks lose on Enron bankruptcy
|
| 11/16/2001 | CV | Cephalon exchanges $73 million convertibles for stock
|
